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Abstract
Objective:Medication adherence among adolescents with cystic fibrosis (CF) is often
suboptimal and this has significant impact on their health and quality of life. The
purpose of the studywas to evaluate the impact of frequent home pulmonary function
(PFT) monitoring on medication adherence among adolescents with CF.
Hypothesis: We hypothesized that weekly home PFT monitoring will improve
adherence while not significantly adding to the treatment burden.
Methods: Individuals aged12-21yearswithCFwereprovided a spirometer tomeasure
PFTs weekly for 1 year. Results were reviewed weekly via telephone. PFT data were
downloaded from the device during quarterly clinic visits. Adherence was calculated
from prescription refill data and compared to the previous year. Perceptions of
treatment burdenwere assessedusing theCFquestionnaire-revised (CFQ-R) quality of
life measure. Health outcome measures including nutritional status and PFTs from
clinic were collected for the study period and the year prior.
Results: Thirty-nine subjects participated in the study. Mean age was 15.89 ± 2.18
years and 54% were female. Mean adherence to weekly spirometry monitoring was
59.47 ± 24.60%. Values generated on the device showed good correlation with those
obtained in clinic. Mean medication possession ratio (MPR) was 60% in the previous
year and 65% during the study (P = 0.04). Mean treatment burden scaled score on the
CFQ-R was 68 at enrollment and 66 at study completion (P = 0.14).
Conclusions: Frequent home PFT monitoring is feasible in CF adolescents and could
successfully improve medication adherence without significantly impacting treatment
burden.
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1 | INTRODUCTION
Adherence to medications is often suboptimal among patients with
chronic diseases like cystic fibrosis (CF). Data from electronic
medication monitoring devices and from analysis of prescription refill
histories reveal adherence rates of 30-75% among individuals with
CF.1–10 Adolescents have significantly lower rates of medication
adherence compared to other age groups.2,3,5,8 Prescription refill data
over a 5-year period revealed adherence rates of 46-65% to pancreatic
enzymes, vitamins, inhaled hypertonic saline (IHS), and dornase alfa
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among patients with CF 13-21 years of age. The same study showed
adherence rates of 73-83% among those 0-5 years of age.2 A different
study evaluated adherence using electronic pill caps and also found
lower rates of adherence to vitamins among adolescents compared to
those less than 12 years of age (57% vs 85%).8
Individuals with CF have a high clinical, psychosocial, and
economic burden that is compounded in the setting of non-
adherence.1–5 Adolescents are particularly vulnerable since there is
a significant decline in pulmonary function (PFT) that occurs during this
time.11,12 An important risk factor for this reduction in PFT is having
frequent pulmonary exacerbations,13 a factor that has been linked to
poor medication adherence.1,3,4 Poor nutritional status is another risk
factor for worsening PFTs among children and adolescents with
CF.13,14 Those who demonstrate good medication adherence have
also been noted to have better weight gain and higher body mass
indices (BMI) irrespective of their age.2,7
Barriers to medication adherence among adolescents with CF
include forgetfulness, competing time pressures, and doubts about the
necessity, or usefulness of the prescribed treatment regimen.11,15–25
There is a decline in parental supervision during adolescence, which
has been shown to negatively impact treatment adherence in this
group.22 Knowledge about the disease, which is often deficient among
adolescents, has also been shown to influence adherence.23 With
worsening disease severity, the complexity of the prescribed
treatment regimen increases in patients with CF.25–27 More treat-
ments are added in an effort to slow down the progression of the
disease. This escalation in treatment complexity has been shown to
adversely affect perceptions of treatment burden, with the effects
being more pronounced among adolescents.25–27 Having a high
perception of treatment burden can negatively impact self-manage-
ment skills and lower adherence.11,16,19,24–26
Many of the same studies that elicited the aforementioned
barriers have also identified multiple adherence motivators such as
recognition of the impact of non-adherence on health outcomes, a
strong relationship with the CF care team and encouragement from
friends and family.11,15–17,19–23,25,26 Interventions that promote self-
management skills, whether they be a knowledge-based intervention
such as providing more education about the disease process and
available treatments, or a behavioral intervention like motivational
interviewing, appear to improve medication adherence in individuals
with CF.11,16,19,25–26,28–35 The use of technology to promote self-
management skills and adherence is becoming increasingly popu-
lar.30–35 Medication reminders have been successful in enabling
patients with CF to take ownership of their disease and have
resulted in improved adherence.11,19,31–33 However, very little data,
exists on the impact of these interventions on the already high
perceptions of treatment burden.
Reviewing PFT results appear to be an adherence motivator for
many adolescents and young adults.17,19,34,35 Home PFT monitoring
has enabled clinicians to obtainmore frequent data and allows patients
the opportunity to readily review and keep track of the results.17,36,37
Lechtzin et al37 conducted a large, randomized controlled trial
evaluating the benefits of early detection of pulmonary exacerbations
on PFT in adults with CF (mean age of 27 years). Participants assigned
to the intervention arm were asked to measure their PFTs and fill out
an online respiratory symptom diary twice a week from home for a
1-year duration. Both of these were viewed in real time by an
electronic monitoring system. Any new symptoms or significant
declines in PFT were identified as potential pulmonary exacerbations
and immediately reported to the care team so an acute/sick clinic visit
could be scheduled. In contrast, participants in the usual care armwere
asked to call the clinic with symptoms and schedule acute/sick visits as
needed for potential exacerbations.
Despite having twice as many acute/sick visits for pulmonary
exacerbations and earlier detection times, the intervention group
did not experience a slower rate of a decline in PFT compared to
the controls.37 Hospitalization rates were also similar between the
groups.37 Not unexpectedly, perceptions of treatment burden
were higher in the intervention arm.37 While several outcome
measures were evaluated in the study, medication adherence was
not one of them. To our knowledge, this is the first study to
evaluate the role of frequent home spirometry in promoting
medication adherence.
This was a prospective interventional study investigating the
impact of frequent home PFT monitoring on medication adherence,
perceptions of treatment burden, and health outcomes among
adolescents with CF. We hypothesized that providing adolescents
withCF the opportunity tomeasure their PFTs fromhomewould result
in improved medication adherence. We also hypothesized that once a
week monitoring of PFTs would not significantly affect perceptions of
treatment burden.
2 | METHODS
Patients with CF 12-21 years of age were invited to participate in the
study. Participants had to have a confirmed diagnosis of CF with a
sweat chloride measurement ≥60mEq/L and/or two disease-causing
mutations and they had to be clinically stable for at least 1 month
prior to enrollment. Eligible participants were approached during
routine clinic visits and provided with information regarding the
study. Those who were interested arranged to meet with the study
team after their clinic visit. Participants were recruited between July
and December 2015 and everyone who was invited agreed to
participate in the study. Written informed consent and/or assent
was obtained from all participants and/or their parents/legal
guardians. The study was approved by the University of Michigan
Institutional Review Board (IRB).
All participants received a Spiro PD® personal spirometer to
monitor their PFTs once a week from home for 12-months. The Spiro
PD® (PMDHealthcare in Allentown, PA), is a FDA approved device. It
generates flow-volume loops and volume-time curves and reports the
forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and
forced expiratory flow between 25% and 75% (FEF25-75) as a percent
predicted using NHANES III reference values. PFTs can be stored and
tracked on the device and downloaded as a PDF.
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Participants were instructed on the correct use of their device
by a respiratory therapist (RT) at enrollment. The RT also ensured
that the demographic information for each participant was
accurately entered into the device. Time was also allotted for
participants to practice using their device while the RT was still
present. Participants were contacted weekly by telephone to
address any questions or concerns with the device and record
PFT results. These telephone calls, which had a specified script, were
made by research assistants and the research coordinator and were
designed primarily to check in with the participants to ensure they
were not having any difficulties with the device. The PFT data
documented through the telephone calls were also meant to serve as
a backup, in case there were any technical difficulties with retrieving
the data from the device. The participants determined the date and
time of the telephone calls. Some of them arranged to call the
research coordinator at a predetermined time every week while
others chose to communicate via text messages. All subjects met
with the study team during their quarterly clinic visits to review
technique, address potential questions and concerns, and download
PFT data from the device.
Adherence was monitored using prescription refill data. A
medication possession ratio (MPR) was calculated for IHS, dornase
alfa, pancreatic enzyme replacement therapy (PERT), and CF vitamins
for the 12-month study period and the 12-months prior to enrollment.
A MPR is calculated by dividing the number of days a medication was
dispensed by the total number of days the medication was prescribed,
within a 365-day period. These four medications were chosen since
they are all routinely prescribed to patients with CF and could provide
valuable information about differences in adherence between inhaled
and oral medications.38,39 Participants were notified at enrollment that
their adherencewould bemonitored andwere asked to provide a list of
pharmacies fromwhere they receive the aforementionedmedications.
Permission was obtained from the participants and/or their parents/
legal guardians to contact the pharmacies for prescription refill data.
The pharmacy list was verified and updated as necessary at each
quarterly visit and upon study completion. Of note, while the weekly
telephone calls addressed barriers to use of the Spiro PD®, it did not
enquire about medication adherence or potential barriers to
adherence.
Perceptions of treatment burden were assessed based on
responses to the CF questionnaire-revised (CFQ-R), a well-
validated, health-related quality of life measure that is specific to
individuals with CF.40 Participants filled out the CFQ-R at
enrollment and end of study. Their responses were used to
calculate a scaled treatment burden score between 0 and 100 for
each time point, with higher scores signifying lower perceptions of
treatment burden. Results of PFTs obtained in clinic, BMI
percentiles, and frequency of pulmonary exacerbations requiring
either oral, or intravenous antibiotics were obtained through
review of the medical records. Values obtained during the study
period were compared to those from the year prior.
Participants received monetary compensation and had the option
of keeping their Spiro PD® at the end of the study.
2.1 | Statistical methods
The Poisson regression model was fitted using generalized estimating
equations to account for within subject correlation to estimate the
change in adherence from that in the 12-months prior to enrollment to
that during the study across the four medications. A MPR was
calculated for the study period and the year prior to enrollment using
the ratio between total days' refilled, or the total number of dayswithin
a 365-day period when the subject was in possession of the
medication, and total days' prescribed, for each of the four
medications. Within the Poisson regression model, the total days'
refilled was used as the outcome and the total days' prescribed was
used as the offset variable.
The intra class correlation coefficient (ICC) was used to assess the
reliability of the FEV1 percent values generated on the device with
those obtained in clinic. A repeated measures analysis using mixed
models was used to model the trajectory of changes in the BMI
percentile and FEV1 percent predicted from the 12-months prior to
enrollment to the 12-month study period. An autocorrelation structure
was used to account for within subject correlation of having repeated
measures on the same subject over time. A piecewise linear regression
allowing for different slopes between pre-study and study periods was
used to estimate the changes on the trajectories due to our
intervention. Generalized estimating equation was used to model
the differences in treatment burden scaled scores between enrollment
and end of study.
3 | RESULTS
Thirty-nine subjects were enrolled in the study. The mean age of the
participants was 15.89 ± 2.18 years and 54%were female. The baseline
demographic characteristics are shown in Table 1. Average training
time was 29.10min, including time spent practicing with the device.
Participants spent an average of 48.28 weeks ± 9.28weeks (range 9-60
weeks) in the study. Mean adherence to weekly spirometry monitoring
was 59.47 ± 24.60% (range 19.44-100%). Nine subjects did not
complete the study but were included in the final analysis. These nine
subjects spent at average of 36.67 weeks ± 13.43 weeks (range 9-52
weeks) in the study. Mean adherence to the weekly spirometry
monitoring in this group was 36.58%± 21.47% (range 17.78-77.78%).
Of the30subjects that completed the study, nine (30%)hadgreater than
80% adherence to the weekly spirometry monitoring.
There was good reliability between the FEV1% predicted values
generated on the Spiro PD®and those obtained in clinic. A comparison
of the mean FEV1% predicted values obtained at the enrollment and
quarterly clinic visits with those generated on the Spiro PD® at or
around the same time is shown in Figure 1. The intra-class correlation
(ICC) between device and clinic values across all visits was high at 0.80.
More specifically, the ICC was 0.90 at enrollment, 0.82 at 3 months,
0.69 at 6 months, 0.99 at 9 months, and 0.95 at 12 months.
There was a significant improvement in adherence across all four
medications during the study as compared to the year prior (P = 0.04).
Table 2 lists theMPR as a percentage for each of themedications in the
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year prior to enrollment and during the study. MPR for all medications
increased during the study period but the change in MPR was similar
across all medications (P = 0.99).
Mean treatment burden scaled score on the CFQ-R was 68 at
enrollment and 66 at the end of the study (P = 0.14). Mean number of
pulmonary exacerbations requiring oral or intravenous antibiotics was
1.90 during the study and in the year prior. Mean FEV1% predicted
declined from 88% to 86% during the study (P < 0.001). However,
there were no significant differences in the rate of decline in FEV1%
predicted during the study as compared to that in the year prior
(P > 0.05). There was also a significant decline in the BMI percentile
from 55% to 52% during the study (P = 0.009). Moreover, the rate of
decline in BMI was higher during the study as compared to that in the
year prior (P = 0.031). However, there was no correlation between
medication adherence during the study and change in treatment
burden scaled scores, FEV1% predicted or BMI percentile (P > 0.05).
4 | DISCUSSION
This was a prospective interventional study evaluating the use of
frequent home spirometry to improve medication adherence among
adolescentswith CF. Subjectsmonitored their PFTsweekly fromhome
for one-year using the Spiro PD®. Adherence to two oral and two
nebulized medications were assessed using prescription refill data.
Medication adherence during the study was compared to that in the
previous year.
The participants in this study were younger than those in the
Lechtzin et al37 home spirometry study (15.89 vs 27.1 years) but could,
nevertheless, be readily trained to measure their PFTs from home.
They were also able to maintain the weekly monitoring for a full year,
similar to the adults in the Lechtzin et al37 study. A pilot study of the
Spiro PD® device demonstrated that it could be successfully used by
patients with CF as young as 11 years of age.17 Although the training
time of 29min might not be feasible in a busy clinic setting, the
participants were trained in the PFT lab after their clinic visit.
Moreover, the 29min also included time spent practicing with the
device with the RT still present to answer questions, which was also
made possible by moving the training away from the clinic area. The
Spiro PD® does come with an instructional video, which could also be
used in the event of a time or space constraint.
The participants in this study were more adherent to the home
spirometry monitoring than the adults in the Lechtzin et al37 study.
While in that study 50% of the participants used the device once a
week and only 19% used the device as instructed for greater than 80%
of the study duration, the participants in this study had a mean
adherence rate of 59.47% and 30% used the device as instructed for
more than 80% of the study.37 One explanation for the better
adherence seen in the participants in this study might be the fact that
they were asked to measure their PFTs only once a week. Parental
supervision may have also contributed to the higher adherence rates
seen in our population. However, Modi et al22 reported a gradual
decline in parental supervision during the teenage years such that for
those who were 15 years of age, only about 10% of their medical care
was supervised by either parent. Perceiving the home spirometry
monitoring as adding to the treatment burden might also influence
adherence. While the participants in this study did not experience a
significant worsening in their perceptions of treatment burden, those
who were randomized to the home spirometry arm in the Lechtzin
et al37 study did. This difference might be due to the varying demands
placed on the participants of the respective studies. Perceptions of
treatment burden may also be higher in adults with CF compared to
adolescents due to corresponding differences in treatment
complexity.27
Participants in this study had bettermedication adherence, even at
baseline, than what has been previously reported in this patient
population.2,3,4–7 Despite that, there was a statistically significant
improvement in adherence across all fourmedications during the study
as compared to the year prior. It is possible that this improvement in
adherence was due to the fact that this was a study monitoring
TABLE 1 Baseline demographics of the study participants
Characteristics
Intervention group
(N = 39) mean (SD)
Age (years) 15.89 (2.18)
% female 54.00
Forced expiratory volume in
1 s (% predicted)
87.51 (19.80)
Body mass index (percentile) 55.23 (25.02)
No. of pulmonary exacerbations
(12 months prior)
1.90 (1.65)
FIGURE 1 Comparison of mean FEV1% predicted from clinic
with that generated on the Spiro PD®
TABLE 2 Medication possession ratio (MPR) by medication type in
the year prior to enrollment and during the study
Medication name Pre-study MPR Study MPR P-value
CF vitamins 56% 61% 0.245
Dornase alfa 66% 71% 0.188
Pancreatic enzymes 55% 59% 0.247
Inhaled hypertonic saline 66% 72% 0.125
Across all medications 60% 65% 0.038
434 | SHAKKOTTAI ET AL.
adherence. In a study by Zindani et al8, knowing that their adherence
was being monitored (through electronic pill caps and empty nebulizer
vials), resulted in adherence rates of 57% to vitamins and 78% to
dornase alfa in the 12 years and older age group. In a different study of
school-aged children, adherence to pancreatic enzymes monitored via
electronic pill caps was 38%.7 While it is not known how adherent the
participants in these different studies were prior to their participation
in those studies, the subjects in this study had an adherence rate of
56% to vitamins, 55% to pancreatic enzymes, 66% to dornase alfa, and
IHS prior to enrollment. Although the telephone calls were carefully
scripted to not discuss medication adherence, it is possible that they
also contributed to the improvements in adherence.
Despite the improvements in medication adherence, there was
no change in frequency of pulmonary exacerbations or in the rate
of decline in FEV1% predicted. These findings were similar to that
in the Lechtzin et al37 study in that even they did not find a
significant difference in the rate of decline in FEV1% predicted
between the two groups. The reduction in FEV1% predicted
observed in this study was lower than that seen by Lechtzin et al37
(−3.58% vs −2%), but this might be due to the younger age of the
participants in this study. More importantly, even with the decline,
the participants continued to maintain normal PFT. Unlike the
Lechtzin et al study,37 the participants in this study experienced a
decline in BMI percentile. Furthermore, it was at a rate that was
higher than that in the previous year. One explanation could be the
small sample size. Even with the decline, the mean BMI remained
above the 50th percentile.
This study had several limitations starting with its small sample
size. Having the participants serve as their own historic controls is
also a limitation since there could be changes in adherence with age
and worsening disease severity that are independent of the
proposed intervention. Another limitation was that adherence was
calculated using prescription refill data and this does not necessarily
reflect whether an individual is taking the medication as instructed.
Furthermore, adherence could be falsely low, particularly for
pancreatic enzymes, due to factors such as overfilling. However,
prescription refill histories provide an objective assessment of
adherence, are less expensive and are more readily available than
electronic medication monitoring devices. Another limitation was
that the selection process did not include factors such as PFTs,
nutritional status or baseline adherence. All eligible individuals who
were willing to participate were recruited for the study. The study
participants had normal PFTs and BMI and a good adherence rate
even in the year prior to enrollment, which might have contributed
to the lack of a more robust response to the intervention. The
selection process also did not take the transition readiness program
that many of the subjects were participating in into account. Since
that also addresses issues like medication adherence and self-
management, it could have influenced the results of this study. Last,
the nine subjects that did not complete the study did not fill out a
final CFQ-R, making it difficult to comment on whether treatment
burden played a role in their decision to not follow through with the
study.
To our knowledge, this was the first study to use frequent home
spirometry to successfully improve medication adherence among
adolescents with CF. Home spirometry can be readily implemented
even in a busy clinic practice. This study used theweekly telephone calls
to checkonpotential difficultieswith the device but they could certainly
beused toprovide real-time feedbackon the spirometry results and that
might potentially improve medication adherence even more. Text
messages are another less time-consuming alternative andone thatwas
preferred by several of the study participants. More studies with larger
sample sizes are needed to further explore the benefits of frequent
home spirometry in improving adherence to treatment, quality of life,
and health outcomes in this vulnerable patient population.
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